MediWound to Supply Pineapple-Based Burn Treatment to U.S. Department of Health

The company’s product NexoBrid is a pineapple enzyme-based topical treatment for the removal of dead tissue from burn wounds

Nasdaq-listed biopharmaceutical company MediWound Ltd. has signed a $16.5 million contract with the U.S. Department of Health and Human Services (HHS) to supply it with its pineapple-based burn treatment drug, the company announced Monday. HHS is set to use NexoBrid, MediWound’s pineapple enzyme-based topical treatment for the removal of dead tissue from burn wounds for public health medical emergencies.

 

The company is expected to begin delivering the product in the first quarter of 2020, with additional deliveries occurring over the following year and a half.

MediWound CEO Sharon Malka. Photo: PR

Founded in 2001 and based in central Israel, MediWound develops and manufactures treatments for severe burns and chronic wounds. In May, the company entered a North America licensing agreement with Nasdaq-listed cell therapies company Vericel Corp. for the exclusive distribution of NexoBrid.